Abstracts » Business

Optimism at Boots

Article Abstract:

Boots shares have been affected by publicity over speculation that retail price maintenance may end for some non-prescription drugs. A sample of six brokers was asked about prospects for the company's shares, and four of the six rate the shares a buy. BZW argues that changes affecting drug pricing are not likely to have much impact. Williams de Broe notes that Boots has increased its market share, and this broker is also a buyer. Panmure Gordon is among brokers rating the shares a hold.

---

Rooting for Boots

Article Abstract:

The share price of Boots is affected by parts of the group which have not performed well such as Fads, but the core drugstore business is performing well. Four brokers of a sample of six rate Boots shares a buy, while two brokers are holders. Buyers include Williams de Broe, UBS, and Mees Pierson. Holders include Societe General Strauss Turnbull which is concerned about the impact on short term earnings of an investment in over-the-counter drugs.

---

Fill your Boots

Article Abstract:

Boots' performance has been boosted by Boots The Chemists, but other activities have had a mixed performance. Four brokers from a sample of six rate the company's stocks a buy, one rates them a hold and one rates them a sell. The buyers are NatWest Securities, BZW, HSBC James Capel and Sutherlands. Williams de Broe is the holder, and the seller is Panmure Gordon which sees the stock price as reflecting the company's strong position.

Drug Store Chains, Chain stores

Some parts © 2012 Advameg, Inc.